Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1152.93 +0.49 (0.04%)
Previous Close $1152.44    52 Week High $88.16 
Open $1150.00    52 Week Low $67.88 
Day High $1157.60    P/E 266.88 
Day Low $1140.27    EPS $4.32 
Volume 4,549,106